GlaxoSmithKline has unveiled a comprehensive restructuring plan aimed at reducing billions of pounds in costs over the next three years, driven by an accelerated adoption of artificial intelligence.
The move includes the closure of its research and development site in Stevenage, Hertfordshire, with staff being relocated to a new facility in Cambridge.
This strategic shift underscores the company’s commitment to leveraging technology to streamline operations and enhance productivity, while also addressing concerns about potential job losses.
The decision to embrace AI as a core component of its cost-cutting strategy reflects a broader trend within the pharmaceutical industry, where companies are increasingly turning to automation and data-driven insights to optimize their workflows.
GSK’s plan is expected to have significant implications for its workforce, particularly in the UK, where the closure of the Stevenage site has sparked fears of a "jobs bloodbath." However, the company has emphasized that the relocation to Cambridge is part of a long-term strategy to position itself at the forefront of innovation in drug discovery and development.
This restructuring comes at a time when the pharmaceutical sector is facing intense pressure to improve efficiency and reduce costs, amid rising R&D expenses and increasing competition.